Business Trends– category –
-
Altris and Northvolt Forge Alliance to Accelerate Next-Gen Sodium-Ion Battery Development in Europe
Altris スウェーデン Overview Swedish materials innovator Altris has partnered with battery giant Northvolt to advance the development of next-generation sodium-ion battery cells. Altris specializes in non-toxic, iron-based cathode materi... -
SK Hynix Validates 12-Die Hybrid Bonded HBM Stack Amidst Heated AI Memory Race
専門メディア South Korea Overview SK Hynix has successfully verified a 12-die HBM stack using hybrid bonding, demonstrating significant progress in its next-generation packaging technology for HBM4 and HBM5. While actively improving yiel... -
Hanmi Semiconductor Unveils Second-Gen Hybrid Bonder for Advanced HBM Stacking, Investing $67M in New Factory
専門メディア South Korea Overview Hanmi Semiconductor is set to introduce its second-generation hybrid bonder prototype this year, crucial for next-generation HBM mass production with over 20 stacked layers. Concurrently, the company is ... -
TSMC’s CoWoS Bottleneck Threatens to Delay Google TPU Mass Production to 2027
専門メディア Taiwan Overview Chronic shortages in TSMC's CoWoS advanced packaging capacity are projected to delay mass production of Google's custom AI chips (TPU) until 2027. Despite TSMC's aggressive expansion plans targeting 120,000 w... -
Curanex Pharmaceuticals Reports Q1 2026 Progress, Phyto-N Advances Towards FDA IND Submission for Ulcerative Colitis and Pipeline Expands to Cancer Cachexia
Taiwan News Taiwan Overview US-based Curanex Pharmaceuticals provided a Q1 2026 update, focusing on its lead drug candidate, Phyto-N. The company is advancing Phyto-N towards a planned Investigational New Drug (IND) submission to the U.S... -
Veritas In Silico Advances mRNA-Targeted Small Molecule Drug Discovery with AI Platform ‘aibVIS,’ Bolstering European Collaborations
Investing.com (Fisco提供) Japan Overview Japanese biotech Veritas In Silico (VIS) is spearheading mRNA-targeted small molecule drug discovery using its proprietary AI platform, "aibVIS." This platform integrates in silico RNA structure a... -
Avidity Biosciences Leads Muscle Disease Therapy with Antibody-Oligonucleotide Conjugates (AOCs): DM1 HARBINGER™ Trial Advances to Phase 3
Bitget Global Overview Avidity Biosciences is a leading company in Antibody-Oligonucleotide Conjugates (AOCs), developing novel RNA therapeutics for muscle diseases. Its lead candidate, delpacibart etedesiran (AOC 1001), is progressing i... -
Contract Organizations’ Pivotal Role in Lentiviral Manufacturing Accelerates Gene Therapy Commercialization
MAI CDMO Global Overview This article highlights the essential role of Contract Development and Manufacturing Organizations (CDMOs) in lentiviral vector manufacturing, crucial for gene and cell therapies like CAR-T. Lentiviral vector pro... -
Silexion Therapeutics Initiates GMP Manufacturing for KRAS-Driven Cancer siRNA Therapy SIL204, Secures Phase 2/3 Trial Approval
Manila Times (via GlobeNewswire) ケイマン諸島 Overview Silexion Therapeutics has commenced GMP clinical batch manufacturing for SIL204, its next-generation siRNA therapeutic targeting mutated KRAS oncogenes. Concurrently, the company rec... -
Zealand Pharma Advances Obesity Pipeline with Phase 3 Progress, Leveraging Roche and Boehringer Ingelheim Partnerships
WhaleWisdom Global Overview Zealand Pharma, in partnership with Roche, is progressing its obesity drug candidate petrelintide into Phase 3 trials following favorable Phase 2 data on weight loss and tolerability. Separately, Boehringer In...
